Picture EBD Group BIO-Europe 2019 Hamburg Germany BEU2019 650x80px
Organisation › Details

Alzheimer’s Disease Neuroimaging Initiative (ADNI)

The Alzheimer’s disease Metabolomics Consortium has partnered with the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to enable adding rich metabolomics datasets to all subjects enrolled in the ADNI study. These metabolomics datasets are meant to inform about metabolic failures across trajectories of disease and to complement genetic and imaging data within ADNI. In phase 1, we profiled blood samples from ADNI 1/GO/2 baseline using 8 complementary metabolomics and lipidomics targeted and non-targeted platforms. In phase 2, we will be profiling longitudinal samples from all ADNI studies covering over 5,000 samples. ADNI is a landmark public-private partnership that began in 2004 as a longitudinal, naturalistic study of older individuals with either Alzheimer’s disease, mild cognitive impairment (MCI), or no cognitive impairment at baseline enrolment. *


Period Start 2004-01-01 established
Product Industry metabolomics
  City n. a. 
    Address record changed: 2018-08-15
Basic data Employees n. a.
    * Document for �About Section�: Biocrates Life Sciences AG. (7/25/18). "Press Release: AAIC Researchers Report New Data on How Gut Bacteria and Lipid Metabolism May Influence Alzheimer’s and Other Brain Diseases". Innsbruck.
Record changed: 2018-08-15


Picture [LSA] – The Business Web Portal 650x89px

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px

» top